专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050260215A1 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate 审中-公开
标题翻译：修饰的超抗原和寻靶化合物之间的缀合以及缀合物的使用
公开(公告)号：US20050260215A1
公开(公告)日：2005-11-24
申请号：US11193748
申请日：2005-07-29
申请人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
发明人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , C07K14/31 , C07K16/30 , C07K16/32 , C07K16/46 , C07K19/00 , C12N15/00 , C12N15/01 , C12P21/02 , C12R1/44
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6863 , A61K2039/505 , C07K14/31 , C07K16/3046 , C07K19/00 , C07K2317/55 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： Methods of lysing cells associated with a disease condition, and method of treating a disease condition by lysing cells associated with the condition, by administering to a mammal a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide that is derived from Staphylococcal enterotoxin A, that has the ability to bind to a Vβ of a T cell receptor and has been modified at amino acid position 47, 128, 187, 225 or 227, in order to have reduced ability to bind to MHC class II antigens.
摘要翻译：通过向哺乳动物施用治疗有效量的包含生物特异性亲和对应物和衍生自葡萄球菌的肽的缀合物来治疗与疾病状况相关的细胞的裂解方法和通过裂解与病症相关的细胞来治疗疾病状况的方法肠毒素A，其具有结合T细胞受体的Vbeta的能力，并且已经在氨基酸位置47,128,187,225或227处被修饰，以便具有降低与MHC II类抗原结合的能力。

2. 发明授权

US07226601B1 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate 失效
标题翻译：修饰的超抗原和寻靶化合物之间的缀合以及缀合物的使用
公开(公告)号：US07226601B1
公开(公告)日：2007-06-05
申请号：US08765695
申请日：1995-06-07
申请人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
发明人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
IPC分类号： C07K16/46 , C07K19/00 , A61K39/395
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6863 , A61K2039/505 , C07K14/31 , C07K16/3046 , C07K19/00 , C07K2317/55 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a Vβ of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.
摘要翻译：一种通过施用治疗有效量的包含生物特异性亲和对应物和肽的缀合物来治疗哺乳动物疾病的方法，其中所述肽含有衍生自葡萄球菌肠毒素A的氨基酸序列，其结合到 T细胞受体，并且具有D227A突变，使得肽具有与MHC II类抗原结合的修饰能力。

3. 发明授权

US07226595B2 Modified Chimeric superantigens and their use 有权
标题翻译：改性嵌合超级抗原及其用途
公开(公告)号：US07226595B2
公开(公告)日：2007-06-05
申请号：US10283838
申请日：2002-10-30
申请人： Per Antonsson , Per Bjork , Mikael Dohlsten , Terje Kalland , Lars Abrahmsen , Johan Hansson , Göran Forsberg
发明人： Per Antonsson , Per Bjork , Mikael Dohlsten , Terje Kalland , Lars Abrahmsen , Johan Hansson , Göran Forsberg
IPC分类号： A61K39/00
CPC分类号： C07K16/3023 , A61K38/00 , A61K47/68 , C07K14/31 , C07K16/3046 , C07K19/00 , C07K2317/732 , C07K2319/00
摘要： A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRVβ, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells.In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens.A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs.An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.
摘要翻译：目标寻找部分和修饰的超抗原之间的缀合物，其特征在于超抗原是野生型超抗原（SAI），其中超抗原区（区域I）中的氨基酸残基确定结合TCR，优选TCRVβ，并且T细胞激活已被另一个氨基酸残基替代，同时保留激活T细胞亚群的能力。在优选实施方案中，修饰的超抗原是至少两种野生型超级抗原（SA I，SA II等）之间的嵌合体，其特征在于确定结合TCR和T细胞活化的区域中的一个或多个氨基酸残基已经在各种野生型超抗原。使用前面段落中定义的修饰/嵌合超级抗原的治疗方法。其中提供链间二硫键的半胱氨酸残基已被突变以防止链间二硫键，优选丝氨酸残基用作药物的抗体制剂。

4. 发明申请

US20060062795A1 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate 审中-公开
标题翻译：修饰的超抗原和寻靶化合物之间的缀合以及缀合物的使用
公开(公告)号：US20060062795A1
公开(公告)日：2006-03-23
申请号：US11193869
申请日：2005-07-29
申请人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
发明人： Lars Abrahmsen , Per Bjork , Mikael Dohlsten , Terje Kalland
IPC分类号： A61K39/395 , C07K16/46
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6863 , A61K2039/505 , C07K14/31 , C07K16/3046 , C07K19/00 , C07K2317/55 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： Conjugates comprising a biospecific affinity counterpart and a peptide that is derived from Staphylococcal enterotoxin A, that has the ability to bind to a Vβ of a T cell receptor and has been modified at amino acid position 47, 128, 187, 225 or 227, in order to have reduced ability to bind to MHC class II antigens. Such conjugates are useful, for example, as therapeutic agents, for example, as anti-cancer agents.
摘要翻译：包含生物特异性亲和对应物和衍生自葡萄球菌肠毒素A的肽的缀合物，其具有结合T细胞受体的Vbeta并在氨基酸位置47,128,187,225或227处被修饰的能力，以降低与MHC II类抗原结合的能力。这样的缀合物可用作例如治疗剂，例如作为抗癌剂。

5. 发明申请

US20100166775A1 S100A9 INTERACTION SCREENING METHOD 有权
标题翻译： S100A9交互式筛选方法
公开(公告)号：US20100166775A1
公开(公告)日：2010-07-01
申请号：US12597735
申请日：2008-04-24
申请人： Per Bjork , Fredrik Ivars , Tomas Leanderson
发明人： Per Bjork , Fredrik Ivars , Tomas Leanderson
IPC分类号： A61K39/395 , G01N33/566 , G01N33/567 , G01N33/53 , C07K16/18 , A61P35/00
CPC分类号： C07K14/52 , C07K14/705 , C07K16/18 , C07K2317/56 , C07K2317/76 , G01N33/566 , G01N33/6842 , G01N2333/705 , G01N2333/70503 , G01N2500/00
摘要： A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising: -determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or -determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.
摘要翻译：鉴定用于调节S100A9与配体的相互作用的化合物的方法，包括： - 确定候选化合物是否能够调节S100A9与RAGE的相互作用或S100A9与TLR的相互作用（Toll 或者以确定S100A9与RAGE的结合或S100A9与TLR的结合的方式确定候选化合物是否能够结合S100A9，从而鉴定该化合物是否可用于治疗。

6. 发明授权

US08841421B2 S100A9 interaction screening method 有权
标题翻译： S100A9相互作用筛选方法
公开(公告)号：US08841421B2
公开(公告)日：2014-09-23
申请号：US12597735
申请日：2008-04-24
申请人： Per Bjork , Frederik Ivars , Tomas Leanderson
发明人： Per Bjork , Frederik Ivars , Tomas Leanderson
IPC分类号： C07K16/18 , C07K14/52 , G01N33/566 , G01N33/68 , C07K14/705
CPC分类号： C07K14/52 , C07K14/705 , C07K16/18 , C07K2317/56 , C07K2317/76 , G01N33/566 , G01N33/6842 , G01N2333/705 , G01N2333/70503 , G01N2500/00
摘要： A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising:—determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or—determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.
摘要翻译：鉴定用于调节S100A9与配体的相互作用的化合物的方法，包括： - 确定候选化合物是否能够调节S100A9与RAGE的相互作用或S100A9与TLR的相互作用（Toll 或者 - 以破坏S100A9与RAGE的结合或S100A9与TLR的结合的方式确定候选化合物是否能够结合S100A9，从而鉴定该化合物是否可用于治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式